March 9 (Reuters) – GSK has agreed to sell its worldwide rights to develop and commercialise its experimental liver disease drug linerixibat to Italian pharmaceutical company Alfasigma for an upfront payment of $300 million, the companies said on Monday.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Mrigank Dhaniwala)
Comments